

1 **Viral shedding dynamics reveals sputum as a reliable and cost-saving specimen for SARS-**  
2 **CoV-2 diagnosis within the first 10 days since symptom onset: A prospective cohort study**

3  
4 Jorge Levican, Ph.D.<sup>1\*</sup>, Leonardo I. Almonacid, Ph.D.<sup>1\*</sup>, Gonzalo Valenzuela, M.D.<sup>1</sup>, Tamara  
5 García-Salum, Ph.D.<sup>1</sup>, Luis Rojas, Ph.D.<sup>2,3</sup>, Eileen Serrano<sup>1</sup>, Catalina Pardo-Roa, Ph.D.<sup>1</sup>, Erick  
6 Salinas, R.N.<sup>1</sup>, María José Avendaño<sup>1</sup>, Fabiola Perazzo<sup>1</sup>, Luis Antonio Díaz, M.D.<sup>4</sup>, Sebastián  
7 Valderrama, M.D.<sup>2</sup>, Marcos Ortega, M.D.<sup>5,6</sup>, Adriana Toro, N.P.<sup>7</sup>, Viviana Montecinos, Ph.D.<sup>8</sup>,  
8 Arnoldo Riquelme, M.D.<sup>3</sup>, Rafael A. Medina, Ph.D.<sup>1,9#</sup>

9  
10 <sup>1</sup>Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia  
11 Universidad Católica de Chile, Santiago, Chile.

12 <sup>2</sup>Department of Internal Medicine, School of Medicine, Pontificia Universidad Católica de Chile,  
13 Santiago, Chile.

14 <sup>3</sup> Program of Pharmacology and Toxicology, School of Medicine, Pontificia Universidad Católica  
15 de Chile.

16 <sup>4</sup>Department of Gastroenterology, School of Medicine, Pontificia Universidad Católica de Chile,  
17 Santiago, Chile.

18 <sup>5</sup>Department of Intensive Care Medicine, School of Medicine, Pontificia Universidad Católica de  
19 Chile, Santiago, Chile.

20 <sup>6</sup>Department of Respiratory Medicine, School of Medicine, Pontificia Universidad Católica de  
21 Chile, Santiago, Chile.

22 <sup>7</sup>Pediatric Service, Clínica UC San Carlos, Red Salud UC Christus, Faculty of Medicine,  
23 Pontificia Universidad Católica de Chile, Santiago, Chile.

24 <sup>8</sup>Department of Hematology-Oncology, School of Medicine, Pontificia Universidad Católica de  
25 Chile, Santiago, Chile.

26 <sup>9</sup>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USA.

27

28 # Corresponding Author: Rafael A. medina, [rmedinai@uc.cl](mailto:rmedinai@uc.cl)

29 **Abstract:**

30 **Background:** Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory  
31 syndrome virus (SARS-CoV-2) is challenging global public health, due to an increasing demand  
32 for testing and the shortage of diagnostic supplies. Nasopharyngeal swab (NPS) is considered the  
33 optimal sample for SARS-CoV2 diagnosis and sputum (SPT) has been proposed as an economic  
34 alternative. However, the temporal concordance of diagnosis in NPS and SPT has not been  
35 addressed.

36 **Methods:** Through a longitudinal study we compared the shedding dynamics of SARS-CoV-2  
37 RNA evaluated by RT-qPCR in serially collected SPT and NPS obtained from 82 ambulatory and  
38 hospitalized patients during acute infection and convalescence. The concordance during the  
39 follow-up and cost analysis between both collected specimens was evaluated.

40 **Findings:** We analyzed 379 samples, 177 NPS and 202 SPT. The highest proportion of positive  
41 samples was detected within the first 15 days after the symptoms onset. The median time of  
42 positivity was higher for NPS (median= 25 days) than SPT (median= 21 days). There was no  
43 significant difference in the median RT-qPCR  $C_T$  values between both sample types. The  
44 temporal categorization of matched-paired samples indicated substantial correlation ( $r=0.6023$ )  
45 and substantial agreement (87.23%) during the first ten days since symptoms onset ( $\kappa =$   
46  $0.697$ ). A cost analysis demonstrated a significant saving when the SPT specimen was used.

47 **Interpretation:** Sputum is a feasible and cost-saving alternative to NPS, providing an equivalent  
48 value for the detection and follow-up of SARS-CoV-2 RNA.

49

50 **Funding:** Agencia Nacional de Investigación y Desarrollo (ANID) of Chile, NIH-NIAID USA.

## 51 **Introduction**

52 In December 2019, a cluster of patients with pneumonia of unknown etiology and  
53 epidemiologically linked to a wet market in Wuhan, Hubei, China was described <sup>1</sup>. The disease,  
54 known as COVID-19 has now widely spread in the world. To date a total of 24,997,327 cases and  
55 842,522 deaths have been confirmed globally <sup>2</sup>. The causative agent was found to be a  
56 *Betacoronavirus*, a virus closely related to the Severe Acute Respiratory Syndrome virus (SARS)  
57 that was named SARS-CoV-2 <sup>3</sup>.

58 Nucleic acid screening tests were rapidly developed to detect the SARS-CoV-2 RNA and  
59 currently are widely used to diagnose COVID-19. The World Health Organization (WHO)  
60 recommends that the decision to test should be based on clinical and epidemiological factors, and  
61 the screening protocols should be adapted to the local situation <sup>4</sup>. Although viral  
62 compartmentalization and shedding patterns of COVID-19 are not yet entirely understood, the  
63 NPS has been considered the optimal sample for the detection of SARS-CoV-2 nucleic acids <sup>4,5</sup>.  
64 However, this procedure is invasive and produces discomfort in the patient during sample  
65 collection. Additionally, it frequently induces sneezing or coughing, being able to generate  
66 contaminated droplets with viral particles posing a significant risk to health workers <sup>6</sup>. Of interest,  
67 recent studies have suggested that virus can also be detected for prolonged periods in saliva,  
68 sputum, and tracheal aspirates in patients with diverse clinical outcomes <sup>7-11</sup>, suggesting that they  
69 might be an alternative sample for diagnosis of SARS-CoV-2 infection.

70 In addition, there is an increasing demand for flock swabs, commercial universal transport media,  
71 and personal protective equipment for health personnel worldwide <sup>12</sup>. This shortage is becoming a  
72 worrisome perspective, particularly in low and middle-income countries. Hence, the availability  
73 of alternative sample collection protocols is urgent. Here, we demonstrate that SPT samples yield  
74 consistent results as compared to NPS samples for SARS-CoV-2 RT-qPCR detection,

75 highlighting its use as an alternative sample for the diagnosis and follow-up of SARS-CoV-2  
76 infection during the first ten days after the onset of the symptoms.

77

## 78 **Methods**

### 79 **Patients and sample collection**

80 A longitudinal study was conducted, including 82 patients diagnosed with COVID-19 in  
81 Santiago, Chile, between March 4th and July 30, 2020. The initial diagnosis was made by RT-  
82 qPCR of RNA extracted from a NPS performed at the Clinical Molecular Virology Laboratory of  
83 the UC-Christus Health network. Once COVID-19 diagnosis was confirmed, hospitalized or  
84 outpatients were invited to participate in the protocol. Written informed consent was obtained  
85 under protocol 16-066, which was reviewed and approved by the Scientific Ethics Committee at  
86 Pontificia Universidad Católica de Chile (PUC). Clinical and epidemiological data, along with  
87 clinical respiratory specimens (NPS and SPT) were serially collected by a trained nurse on days 1  
88 to 36 after symptoms onset. NPS collection was conducted according to standard protocols. For  
89 SPT collection, patients were asked to voluntary cough and deposit the expectorated secretion in  
90 a sterile specimen container with 2 mL of saline phosphate solution. Samples were transported to  
91 the laboratory and processed the same day. The demographic and clinical characteristics of  
92 patients are described in Table 1.

93

94 **RNA extraction and SARS-CoV-2 RNA amplification.** The samples were subjected to RNA  
95 extraction using TRIzol LS<sup>TM</sup> (Thermo Fisher Scientific), and SARS-CoV-2 RNA was detected  
96 using real-time one-step RT-qPCR targeting Orf1b with dual-labeled hydrolysis probe  
97 (6FAM/TAMRA) as previously reported with some modifications<sup>13</sup>. Detailed protocol in  
98 Appendix 1.

99

100 **RT-qPCR analytical validation.** Identity of sequence of primers and probe regarding the virus  
101 circulating in Chile, linear range (Supplementary Figure 1), limit of detection, specificity and  
102 matrix interference (Supplementary Figure 2) were determined in the analytical validation of the  
103 test. Detailed protocols are described in Appendix 2.

104

### 105 **Statistical and cost analyses**

106 Categorical parameters were expressed as frequencies (%), whereas continuous variables are  
107 presented as median (interquartile range [IQR]). Categorical characteristics comparison was  
108 performed with Chi-squared test. Agreement of the results between NPS and SPT specimens was  
109 assessed using Kappa statistics. According to Landis and Koch, Cohen's kappa coefficient was  
110 defined as 0.00 - 0.20 = slight, 0.21- 0.40 = fair, 0.41-0.60 = moderate, 0.61-0.80 substantial and  
111 0.81–1 = almost perfect agreement<sup>14</sup>. Kruskal-Wallis and Mann-Whitney U-test were used to  
112 evaluate differences between continuous variables, and Spearman's correlation to assess the  
113 relation between NPS and SPT C<sub>T</sub>s. Kaplan-Meier estimator and Log-rank were used to evaluate  
114 differences in the positivity distribution over time. Wilcoxon matched-pairs signed rank test was  
115 used to compare matched C<sub>T</sub> pairs.

116 Cost analyses of collecting SPT versus NPS specimens were performed considering 1,000  
117 samples. We evaluated one healthcare network provider (UC-Christus Hospital) and one private  
118 healthcare provider (private diagnostic laboratory). The cost of reagents was obtained directly  
119 from vendors or the inventory of the UC-Christus Hospital. We assessed the cost differences of  
120 obtention the SPT specimen as a self-collection procedure, with and without a health care worker  
121 assistance as compared to obtain NPS specimen, which requires a trained health care worker, a  
122 flock swab and a collection tube containing universal transport medium (UTM)(Table S1). A *p*-

123 value <0.05 was considered statistically significant. Statistical analyses were conducted using  
124 PRISM 8.0 (v8.4.2).

125

## 126 **Role of the funding source**

127 The funders had no role in study design; in the collection, analysis, and interpretation of data; in  
128 the writing of the report; and in the decision to submit the paper for publication. The  
129 corresponding author RAM, confirms that he had full access to all the data in the study and had  
130 final responsibility for the decision to submit for publication.

131

## 132 **Results**

### 133 **SARS-CoV-2 RNA is detectable in SPT and NPS samples at comparable proportions during** 134 **the early stages of COVID-19.**

135 Eighty-two patients were recruited for our longitudinal study (Table 1). Thirty-seven patients  
136 showed mild symptoms and did not require hospitalization, while 45 showed moderate to severe  
137 symptoms and were admitted to the hospital one to 15 days after the onset of symptoms. Of these,  
138 35.6% required ICU and one patient died. For the inpatients, 66.7% were men and had a median  
139 age significantly higher than outpatients (55 vs. 33 years of age, respectively). Their principal  
140 clinical manifestations were dyspnea and severe fatigue. In outpatients the main clinical  
141 symptoms included sore throat, chills, headache, myalgia and the sensorial symptoms, anosmia  
142 and ageusia. Pre-existing conditions, including hypertension and prediabetes or non-alcoholic  
143 steatohepatitis (NASH) were more prevalent for inpatients and, allergic disease was more  
144 predominant for outpatients.

145 A total of 379 samples, 177 NPS, and 202 SPT were obtained (one to five samples were obtained  
146 per patient). Overall, 112 (63.28%) NPS and 91 (45.05%) SPT samples were positive for SARS-

147 CoV-2 and were distributed along the entire period of study, with the last positive sample  
148 detected in NPS at day 34 and at day 29 in SPT. In a detailed case-by-case analysis, we observed  
149 discontinuous viral RNA detection, i.e., after a negativization, the SARS-CoV-2 RNA was  
150 detected in a posterior sample. This dynamic was observed in ten of the 82 analyzed patients  
151 (12.2%), with six of them found only in NPS, three only in SPT and one in both sample types.  
152 Temporal stratification of SARS-CoV-2 RNA detection, showed that 77.27% of the samples were  
153 positive within the first five days post symptoms onset while the accumulated positivity reached  
154 70.45% before 15 days (Table S1). To study the overall dynamics of viral RNA shedding in NPS  
155 and SPT over time, we used the Kaplan–Meier method. We observed a sustained decline in  
156 positivity during the time of the study, with no significant difference between the two sample  
157 types throughout the entire evaluated period (Log-rank test  $p=0.0623$ ) (Figure 1). The same  
158 analysis showed that the median time of positivity (days at which the positivity in each group was  
159 50%) was 21 days for SPT and 25 days for NPS. Similarly, when we separated the patients by  
160 severity, we observed a median time of positivity of 20 days for SPT and 23 days in NPS for  
161 outpatients (Log-rank test  $p=0.4671$ ) and 21 days in SPT and 26 days in NPS for hospitalized  
162 patients (Log-rank test  $p=0.0650$ ) (Supplementary Figure 3A and 3B). These data suggest that  
163 SARS-CoV-2 RNA excretion in NPS is more prolonged than SPT especially in a severe clinical  
164 context. Remarkably, we observed that RNA positivity in SPT was in high agreement with NPS  
165 during the first ten days. After this time, the positivity rate of both sample types shows a  
166 divergent pattern, suggesting a decrease in concordance (Figure 1A). A similar finding was  
167 obtained when the analysis was conducted separately in outpatients or hospitalized patients  
168 (Supplementary Figure 3A and 3B).

169 Subsequently, we compared the overall RT-qPCR  $C_T$  values of the positive NPS and SPT  
170 samples. The median  $C_T$  for NPS was 31.71 (IQR, 27.45-35.14) with a range of 13.6 to 38.87,

171 and the median  $C_T$  for SPT was 31·19 (IQR, 27·64-35·27) with a range of 16·5 to 38·07. No  
172 significant differences were found between the two groups ( $p=0·9108$ ) (Figure 1B). The same  
173 was true when we analyzed the  $C_T$  grouped by severity. The median  $C_T$  for NPS was 32·63 (IQR  
174 28·69-35·2) and for SPT was 33·17 (IQR 28·48-35·53) in hospitalized patients ( $p=0·6106$ ), while  
175 for ambulatory patients the median was 30·78 (IQR 24·53-34·61) for NPS and 29·85 (IQR 23·99-  
176 34·35) for SPT ( $p=0·7995$ ). Although approximately two to three  $C_{TS}$  higher were observed in the  
177 samples obtained from hospitalized patients than outpatients, this difference was not statistically  
178 significant ( $p=0·1431$ ). As we expected, the highest viral loads (e.g. lower  $C_T$  values) were found  
179 at the first days of the patients follow up (up to 10 days after symptoms onset). When we  
180 analyzed the  $C_{TS}$  values over time, we observed a sustained decrease of viral load after the initial  
181 peak. Logistic regression analysis showed slopes of 0·5344 (95% CI= 0·3678-0·701) and 0·5685  
182 (95% CI=0·4183-0·7187) for NPS and SPT respectively, with no significant differences  
183 ( $p=0·7640$ ) (Figure 1C). While the Y-intercept was significant lower ( $p=0·0004$ ) for NPS (29·14,  
184 95% CI=26·17-32·11) than SPT (32·09, 95% CI= 29·36-34·82)(Figure 1C), this difference could  
185 be explained because of the prolonged shedding of viral RNA in NPS than SPT. This was  
186 reflected in the overall data set, where there are more abundant negative results ( $C_T=$  or  $>$  to  
187 39·02) in SPT than NPS, which resulted in an increased median  $C_T$  value of SPT. Thus, we  
188 conducted logistic linear regression including only the positive  $C_{TS}$  (Figure 1D) for both sample  
189 types and we observed no significant difference in the slopes (0·3096, 95% CI=0·1804-0·4388 for  
190 NPS and 0·2890 95% CI=0·1337-0·4444 for SPT,  $p=0·8411$ ) and the Y-intercept (26·17, 95%  
191 CI=24·15-28·18 for NPS and 27·09, 95% CI=24·92-29·26 for SPT  $p=0·3768$ ). Overall, this  
192 suggests that the shedding dynamics in these two samples types are highly similar.

193

194 **SPT has high concordance with NPS SARS-CoV-2 RNA detection during the first ten days**  
195 **of symptoms.**

196 To compare the agreement and correlation of NPS vs. SPT, in detecting SARS-CoV-2 RNA over  
197 time, 167 paired samples representing 34 days of follow up of 71 patients (30 outpatients and 41  
198 hospitalized) were analyzed. One-hundred and three NPS (61.68%) and 76 SPT (45.51%)  
199 resulted positive for SARS-CoV-2 RNA, this data indicated a fair agreement (65.87%,  
200 Kappa=0.374, 95% CI 0.197-0.466) and overall Spearman's correlation of  $r=0.4790$  (95%  
201 CI=0.3489 to 0.5911,  $p<0.0001$ ) (Table 2, Figure 2A).

202 Given that our results indicate an increased shedding of viral RNA during the first days after the  
203 symptoms onset, we stratified the data according to the temporal variable and conducted  
204 correlation and agreement analyses. The analysis showed a robust correlation in the early period  
205 of the study. In terms of positivity, the analysis of the first ten days after symptoms onset shows  
206 only one case of discrepancy for NPS and five for SPT with substantial to almost perfect  
207 agreement (87.23%, Kappa=0.697, 95% CI=0.477-0.918). In addition, when we compared the  $C_T$   
208 values obtained with both sample types in this period we observed a strong correlation ( $r=$   
209  $0.6023$ , 95% CI=  $0.3736$  to  $0.7620$ ,  $p< 0.0001$ ) (Table 2, Figure 2B). Similar results were  
210 observed for the first ten days, and only moderate correlation and slight agreement was observed  
211 after ten days of symptoms onset ( $r=0.4426$ , Kappa=0.177 95% CI=0.016-0.339) (Figure 2C,  
212 Table 2). The same was true when we compared the  $C_T$  values from NPS and SPT in matched-  
213 paired samples collected simultaneously from the same individual. We found significant  
214 differences between the  $C_{TS}$  of two sample types when the overall data set was compared  
215 ( $p=0.0001$ ) (Figure 2D). Remarkably, when we compared paired  $C_{TS}$  from the two sample types  
216 from 47 patients collected before ten days after symptoms onset, we found no significant  
217 differences between the groups ( $p=0.0797$ ) (Figure 2E), while a significant difference was

218 observed after ten days ( $p=0.0004$ )(Figure 2F). These data confirm that SPT is a feasible sample  
219 to detect SARS-CoV-2 and offers remarkable agreement with the results obtained with NPS  
220 sampling during the first ten days after the onset of COVID-19 symptoms.

221  
222 **SPT specimen is a cost-saving alternative for the diagnosis of SARS-CoV-2 in a clinical**  
223 **setting.**

224 Assuming equivalent clinical efficacy between NPS and SPT within the first ten days since onset  
225 of symptoms, we developed a cost-minimization analysis to evaluate the feasibility of  
226 implementing SPT collection technique in the clinical practice. We estimated the direct and  
227 indirect medical costs associated with the labor hours of healthcare professionals and  
228 consumables associated with taking 1,000 specimens of each type of sample. The costs were  
229 based on 2020 economic variables and expressed in United States Dollars (USD). The economic  
230 data were obtained from a healthcare network setting and a private health diagnostic provider  
231 (Figure 3A). The procedure to obtain NPS specimen, which requires a trained health care worker,  
232 a flock swab and a UTM collection tube, was compared to the collection of a SPT sample  
233 collected by a health care worker or self-collected into a sterile container with saline solution as  
234 stabilizing medium. We found an overall cost reduction ranging from USD 2,340 to USD 5,478  
235 per 1,000 specimens collected in both a health network setting and a private health diagnostic  
236 provider (Figure 3B). These analyses indicate that the collection of a SPT specimen provides a  
237 low-cost alternative for SARS-CoV-2 diagnosis.

238  
239 **Discussion.**

240 Currently there are scarce studies on the performance of different types of samples in the  
241 molecular diagnosing of SARS-CoV-2. Through a prospective cohort study, we demonstrate that

242 SPT can be a valuable and cost-saving alternative sampling technique for COVID-19 diagnosis.  
243 By including individuals with a wide range of clinical manifestations, we show that this specimen  
244 can be used with an equivalent diagnostic yield as the standard NPS specimen, particularly within  
245 the first ten days since onset of symptoms, regardless of severity. Importantly, as the pandemic is  
246 now impacting the poorest regions of the world, our analyses suggest that this sampling technique  
247 can be easily applied at a fraction of the cost of the conventional NPS, providing an invaluable  
248 tool for community testing and surveillance in resource-limited countries.

249 Nasopharyngeal swab has been extensively used as the gold standard sample for molecular  
250 diagnosis of upper respiratory tract viral infections <sup>19</sup>. In addition, other samples of the upper  
251 respiratory tree have been used for diagnosis, such as oro- and retropharyngeal swabs, saliva and  
252 sputum, and invasive samples such as bronchoalveolar lavage or tracheal aspirate have also been  
253 used <sup>20</sup>. The choice of clinical specimen depends on the particular clinical condition of the  
254 individual and the clinical sensitivity of the test and the area sampled <sup>20, 19</sup>. In the theory, the  
255 successful use of these samples ultimately is affected, in one hand, by the compartmentalization  
256 and timing of viral replication of each virus in the respiratory tract, and in the other hand, the  
257 timing of collection of the specimen. In the practice, the issue is obviously more complex and  
258 there is some level of discrepancy. Kim et al., described that adenoviruses and the endemic  
259 human coronaviruses are most frequently isolated from saliva, while influenza A and human  
260 rhinoviruses are isolated from NPS, concluding that no sampling method was consistently more  
261 sensitive than another <sup>21</sup>. However, a different study found that sputum samples were  
262 significantly better than the NPS for the detection of influenza A, respiratory syncytial virus,  
263 human rhinovirus A, coronavirus OC43, and adenovirus in individuals with an acute respiratory  
264 infection <sup>22</sup>.

265 Early on during the pandemic outbreak it was shown that SARS-CoV-2 RNA could be detected  
266 in bronchoalveolar lavage fluid (BLF), pharyngeal swabs, posterior oropharyngeal saliva,  
267 fibrobronchoscopy brush biopsies, stool, sputum, blood and nasal swabs in COVID-19 patients.  
268 Wang et al., observed that BLF (98%), sputum (72%) and nasal swabs (63%) were the samples  
269 that gave the most consistent results for viral RNA detection <sup>9</sup>. In addition, a recent longitudinal  
270 study suggests that saliva samples are more sensitive for the detection of SARS-CoV-2 in  
271 COVID-19 hospitalized patients than NPS specimens <sup>17</sup>. Similarly, To et al, (2020) in an  
272 observational COVID-19 cohort study of patients from two hospitals in Hong Kong, concluded  
273 that posterior oropharyngeal saliva samples are a non-invasive specimen more acceptable to  
274 patients and healthcare workers <sup>15</sup>. In agreement, our study supports the use of SPT as an  
275 equivalent specimen to the NPS at early time points during infection.

276 These studies also showed that viral titers peak soon after symptom onset, and that higher viral  
277 loads were detected in the nose than the throat <sup>9,15,16</sup>. In our study, we showed that viral RNA  
278 could be detected for up to 4 weeks (or more days in some patients) and there are frequent  
279 instances where individuals show discontinuous RNA detection, a phenomenon that was also  
280 observed in other studies <sup>11,15-17</sup>. Although the precise timing and localization of viral replication  
281 requires more comprehensive research, recent evidence shows that angiotensin I converting  
282 enzyme 2 (ACE2 gene product), the receptor for the SARS-CoV-2 virus, is widely expressed in  
283 the respiratory tract and there is remarkably high expression level of ACE2 in secretory goblet  
284 cells and on nasal epithelial cells <sup>18</sup>. This suggests that, at least in the first stage of the disease,  
285 high levels of replication could occur at these sites resulting in the detection of RNA from these  
286 samples <sup>18</sup>.

287 Our cohort included individuals with a wide range of disease severity. This allowed us to  
288 determine that severity does not play a role in the detection of SARS-CoV-2 RNA in NPS and

289 SPT samples by RT-qPCR, finding no significant differences in their diagnostic capacity during  
290 the first ten days after the onset of the symptoms. The longitudinal analysis of positive samples  
291 showed increased viral loads during the first week (lower  $C_{TS}$ ) and a gradual decrease over the  
292 following weeks, which was associated with the resolution of symptoms <sup>9,16</sup>. Noteworthy,  
293 although no statistically significant, there was a slightly higher  $C_T$  (approximately two to three  
294  $C_T$ ) values in hospitalized as compared to outpatients in both sample types. This difference could  
295 be explained because of more prolonged times of RNA excretion in hospitalized compared to  
296 ambulatory patients (the more delayed RNA excretion the higher the  $C_T$  at late time points).  
297 Accordingly, we observed higher median time of positivity in NPS for hospitalized patients (26  
298 days) than ambulatory patients (23 days) while it was relatively constant in SPT (20 days for  
299 hospitalized vs 21 for ambulatory patients). Although not statistically significant, this data  
300 suggests that RNA excretion in NPS is more prolonged than SPT especially in a severe clinical  
301 context.

302 Our longitudinal study also allowed us to evaluate the correlation and consistency of using STP  
303 and NPS over time. We observed a gradual loss of correlation of NPS and SPT detection after ten  
304 days of follow up, which was concomitant with discontinuous detection of viral RNA in both  
305 sample types. We discarded analytical drawbacks that could be associated with matrix  
306 interference or loss of sensitivity in the RT-qPCR. In our study the NPS and SPT were collected  
307 by one trained nurse concurrently, transported immediately to the laboratory at 4°C, and  
308 processed on the day of collection. Hence, technical drawbacks related to the sample collection  
309 are unlikely to explain this loss of correlation seen after the ten days. We hypothesized that our  
310 ability to detect viral RNA with the different specimens could be a reflection of the timing of  
311 replication of the virus in the nasopharyngeal cavity versus the other respiratory tract sites during  
312 COVID-19 disease. It is plausible that after ten days in most cases the virus could be replicating

313 at low levels and only in restricted areas of the respiratory tract. Alternatively, we could be  
314 detecting traces of SARS-CoV-2 RNA remaining and not necessarily active viral replication. This  
315 agrees with previous reports showing that the virus can be isolated in culture only within the first  
316 week after the symptoms onset in sputum <sup>11</sup>. Overall, our findings indicate that the timing and  
317 sampling site must be carefully considered for diagnosis and there is a need to design cohort  
318 studies to further characterize the natural infection of COVID-19 patients longitudinally.

319 The COVID-19 pandemic has expanded rapidly worldwide and currently Latin America has  
320 become the epicenter of the pandemic, stressing health systems and causing large economic  
321 losses <sup>25-27</sup>. SARS-CoV-2 is highly transmissible in the general population <sup>28,29</sup>, which has  
322 highlighted the need to improve active surveillance, early detection, isolation and tracking of  
323 COVID-19 cases as a fundamental part of control strategies <sup>30</sup>. The ease of obtaining a SPT  
324 sample, which can be self-collected, together with our costs analysis demonstrated that the use of  
325 this sample type is a cost-saving and suitable alternative for SARS-CoV-2 detection. Importantly,  
326 we show that it has a similar diagnostic value as NPS when obtained within the first ten days  
327 since of symptom onset. In addition, the use of alternative sample collection, such a SPT  
328 specimens, should be included in the context of active surveillance and in the clinic upon  
329 confirming the timing of onset of symptoms. Overall, this strategy can help relieving some  
330 economic, logistic and biosecurity constraint associated to the use of NPS.

331 **Contributors**

332 J.L. and L.I.A. designed experiments, acquire and analyzed the data, prepared illustrations, and  
333 wrote the paper. G.V., F.P., T.G.S., M.J.A obtained and analyzed clinical metadata, prepared  
334 tables and wrote the paper. L.R. analyzed the data, prepared illustrations, and wrote the paper.  
335 Ei.S. and C.P. analyzed the data and wrote the paper. Er.S, L.A.D., S.V., M.O., A.T. recruited  
336 patients and collected clinical metadata and revised the paper. V.M. provided funding and  
337 resources and wrote parts of the paper. A.R. recruited patients and collected clinical metadata,  
338 analyzed the data and wrote the paper. R.A.M. obtained funding, conceived and supervised this  
339 study, designed experiments, analyzed the data, prepared illustrations, and wrote the paper.

340

341 **Declaration of interest**

342 We declare no competing interest.

343

344 **Acknowledgment**

345 Protocols and the study set-up used for this study were based on influenza virus studies  
346 established in part with the support of the FONDECYT 1161971 and ACT 1408 grants from the  
347 Agencia Nacional de Investigación y Desarrollo (ANID) from Chile, the FLUOMICS  
348 Consortium (NIAID grant U19AI135972) funded by NIH and with funding from CRIP (Center  
349 for Research on Influenza Pathogenesis), an NIH funded Center of Excellence for Influenza  
350 Research and Surveillance (CEIRS, contract number HHSN272201400008C) to RAM. Special  
351 thanks to Leandro Fernandez García, for technical assistance in the preparation of synthetic  
352 SARS-CoV-2 RNA standard.

## 353 References

- 354 1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in  
355 China, 2019. *New England Journal of Medicine* 2020.
- 356 2. Medicine JH. COVID-19 Dashboard by the Center for Systems Science and Engineering  
357 (CSSE). 2020.
- 358 3. of the International CSG. The species Severe acute respiratory syndrome-related  
359 coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nature Microbiology* 2020;  
360 **5**(4): 536.
- 361 4. Organization WH. Laboratory testing for coronavirus disease 2019 (COVID-19) in  
362 suspected human cases: interim guidance, 2 March 2020: World Health Organization, 2020.
- 363 5. CHENG MP, PAPENBURG J, DESJARDINS M. original: Diagnostic Testing for Severe  
364 Acute Respiratory Syndrome–Related. *N Engl J Med* 2020; **382**: 727-33.
- 365 6. Qian Y, Zeng T, Wang H, et al. Safety management of nasopharyngeal specimen  
366 collection from suspected cases of coronavirus disease 2019. *International Journal of Nursing*  
367 *Sciences* 2020.
- 368 7. Xu K, Lu X, Wei G, Zhou J, Fang Q, Cai H. Viral load dynamics and disease severity in  
369 patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020:  
370 retrospective cohort study.
- 371 8. Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. *Jama*  
372 2020.
- 373 9. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical  
374 specimens. *Jama* 2020; **323**(18): 1843-4.
- 375 10. Di Guardo G. SARS-CoV-2 infection's pathogenesis: Take-home messages from other  
376 pathogens. 2020.
- 377 11. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized  
378 patients with COVID-2019. *Nature* 2020; **581**(7809): 465-9.
- 379 12. Ranney ML, Griffeth V, Jha AK. Critical supply shortages—the need for ventilators and  
380 personal protective equipment during the Covid-19 pandemic. *New England Journal of Medicine*  
381 2020; **382**(18): e41.
- 382 13. Chu DK, Pan Y, Cheng SM, et al. Molecular diagnosis of a novel coronavirus (2019-  
383 nCoV) causing an outbreak of pneumonia. *Clinical chemistry* 2020; **66**(4): 549-55.
- 384 14. Landis JR, Koch GG. The measurement of observer agreement for categorical data.  
385 *biometrics* 1977: 159-74.
- 386 15. To KK-W, Tsang OT-Y, Leung W-S, et al. Temporal profiles of viral load in posterior  
387 oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2:  
388 an observational cohort study. *The Lancet Infectious Diseases* 2020.
- 389 16. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of  
390 infected patients. *New England Journal of Medicine* 2020; **382**(12): 1177-9.
- 391 17. Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva is more sensitive for SARS-  
392 CoV-2 detection in COVID-19 patients than nasopharyngeal swabs. *Medrxiv* 2020.
- 393 18. Sungnak W, Huang N, Bécavin C, et al. SARS-CoV-2 entry factors are highly expressed  
394 in nasal epithelial cells together with innate immune genes. *Nature medicine* 2020; **26**(5): 681-7.
- 395 19. Meerhoff T, Houben M, Coenjaerts F, et al. Detection of multiple respiratory pathogens  
396 during primary respiratory infection: nasal swab versus nasopharyngeal aspirate using real-time  
397 polymerase chain reaction. *European journal of clinical microbiology & infectious diseases*  
398 2010; **29**(4): 365-71.

- 399 20. Charlton CL, Babady E, Ginocchio CC, et al. Practical guidance for clinical microbiology  
400 laboratories: viruses causing acute respiratory tract infections. *Clinical microbiology reviews*  
401 2018; **32**(1).
- 402 21. Kim Y-g, Yun SG, Kim MY, et al. Comparison between saliva and nasopharyngeal swab  
403 specimens for detection of respiratory viruses by multiplex reverse transcription-PCR. *Journal of*  
404 *clinical microbiology* 2017; **55**(1): 226-33.
- 405 22. Jeong JH, Kim KH, Jeong SH, Park JW, Lee SM, Seo YH. Comparison of sputum and  
406 nasopharyngeal swabs for detection of respiratory viruses. *Journal of medical virology* 2014;  
407 **86**(12): 2122-7.
- 408 23. Voynow J, Rubin B. Mucins, mucus, and airway secretions. *CHEST* 2009; **135**: 505-12.
- 409 24. Kelly MM, Efthimiadis A, Hargreave FE. Induced sputum. *Human Airway*  
410 *Inflammation*: Springer; 2001: 77-91.
- 411 25. Murray C. Forecasting the impact of the first wave of the COVID-19 pandemic on  
412 hospital demand and deaths for the USA and European Economic Area countries. 2020.
- 413 26. Burki T. COVID-19 in Latin America. *The Lancet Infectious Diseases* 2020; **20**(5): 547-  
414 8.
- 415 27. Quaresima V, Naldini MM, Cirillo DM. The prospects for the SARS-CoV-2 pandemic  
416 in Africa. *EMBO Molecular Medicine* 2020: e12488.
- 417 28. Barrett ES, Horton DB, Roy J, et al. Prevalence of SARS-CoV-2 infection in previously  
418 undiagnosed health care workers at the onset of the US COVID-19 epidemic. *medRxiv* 2020.
- 419 29. Chen Y, Tong X, Wang J, et al. High SARS-CoV-2 Antibody Prevalence among  
420 Healthcare Workers Exposed to COVID-19 Patients. *Journal of Infection* 2020.
- 421 30. Organization WH. Surveillance strategies for COVID-19 human infection. 2020.

422

423 **Tables**

424 **Table 1. Demographic and baseline characteristics of patients infected with SARS-CoV-2**

	Outpatients (n = 35)	Inpatients (n = 45)	P value
<b>Characteristics</b>			
Age, median years (range)	33 (14-89)	<b>55 (0.75-83)</b>	0.001*
<b>Sex</b>			
Female, n (%)	19 (54.3%)	15 (33.3%)	0.060
Male, n (%)	16 (45.7%)	30 (66.7%)	
<b>Symptoms</b>			
<b>Respiratory</b>			
Dyspnea, n (%)	4 (11.4%)	<b>24 (53.3%)</b>	<0.001*
Chest discomfort, n (%)	1 (2.9%)	6 (13.3%)	0.100
Cough, n (%)	24 (68.6%)	37 (82.2%)	0.155
Runny nose, n (%)	10 (28.6%)	8 (17.8%)	0.251
Sore throat, n (%)	<b>13 (37.1%)</b>	4 (8.9%)	0.002*
<b>Constitutional</b>			
Fever, n (%)	27 (77.1%)	31 (68.9%)	0.412
Chills, n (%)	<b>15 (42.9%)</b>	6 (13.3%)	0.003*
Headache, n (%)	<b>27 (77.1%)</b>	11 (24.4%)	<0.001*
Myalgia, n (%)	<b>23 (65.7%)</b>	16 (35.6%)	0.007*
Severe fatigue, n (%)	6 (17.1%)	<b>23 (51.1%)</b>	0.002*
<b>Gastrointestinal</b>			
Diarrhea, n (%)	11 (31.4%)	13 (28.9%)	0.806
Nausea/Vomiting, n (%)	6 (17.1%)	5 (11.1%)	0.437
<b>Sensorial</b>			
Anosmia, n (%)	<b>21 (60%)</b>	7 (15.6%)	<0.001*
Ageusia, n (%)	<b>14 (40%)</b>	5 (11.1%)	0.003*
<b>Comorbidities or conditions</b>			
Obesity (BMI ≥ 30), n (%)	6 (17.1%)	<b>17 (37.8%)</b>	0.043*
Hypertension, n (%)	4 (11.4%)	<b>14 (31.1%)</b>	0.036*
Hyperlipidemia, n (%)	3 (8.6%)	10 (22.2%)	0.101
Prediabetes or NASH, n (%)	2 (5.7%)	<b>16 (35.6%)</b>	0.002*
Cardiovascular diseases, n (%)	1 (2.9%)	3 (6.7%)	0.438
Chronic pulmonary diseases, n (%)	4 (11.4%)	4 (8.9%)	0.707
Asthma, n (%)	5 (14.3%)	2 (4.4%)	0.122
Neurological disease, n (%)	1 (2.9%)	5 (11.1%)	0.164
Immuno-rheumatologic diseases, n (%)	1 (2.9%)	7 (15.6%)	0.060
Smoker, n (%)	1 (2.9%)	7 (15.6%)	0.060
Allergic disease, n (%)	<b>9 (25.7%)</b>	3 (6.7%)	0.018*
<b>Duration of symptoms before admission, days (range)</b>	-	7.1 (1-15)	-
<b>Outcomes</b>			
ICU admission, n (%)	-	16 (35.6%)	-
30-Day mortality, n (%)	0	1 (2.2%)	0.375


425 Abbreviations: BMI: Body mass index; NASH: Non-alcoholic steatohepatitis; ICU, Intensive care unit. \*p value  
 426 <0.05, t-test/Chi-square test. Bold font highlight significant values associated to outpatients or inpatients. For two  
 427 patients no clinical data were available.

428 **Table 2. Analyses of paired NPS and SPT samples over time after symptoms onset.**

<b>Range (time)</b>	<b>Observed agreement NPS vs SPT</b>	<b>Kappa value</b>	<b>SE Kappa</b>	<b>95%CI</b>	<b>Agreement*</b>
<b>1-7 days</b>	89·29%	0·661	0·144	0·309-1	Substantial
<b>1-10 days</b>	87·23%	0·697	0·112	0·477-0·918	Substantial
<b>11-34 days</b>	57·60%	0·177	0·083	0·016-0·339	Slight
<b>1-34 days</b>	65·87%	0·331	0·066	0·197-0·466	Fair

429 \*According Landis and Koch<sup>14</sup>.

430 **Figures**



431


432 **Figure 1. SARS-CoV-2 RNA is detectable in SPT and NPS samples at similar levels during**  
433 **the early stages of COVID-19. A.** Percentage of SARS-CoV-2 RNA positive samples over time.

434 Frequency of viral RNA detection was estimated using the Kaplan–Meier method. Log-rank  
435 (Mantel-Cox) test was applied to evaluate the difference in the duration of viral RNA shedding in  
436 the NPS (blue line) and SPT (red line) groups (95% CI are represented with the same colors) **B.**

437 Overall comparison  $C_T$  from SARS-CoV-2 RNA positive samples. Median and range of  $C_T$ s from  
438 NPS (n=112, blue box) and SPT (n=91, grey box) SARS-CoV-2 RNA positive cases. Non-  
439 parametric unpaired Mann-Whitney test was conducted to compare  $C_T$ s from NPS and SPT. **C.**

440 Temporal distribution of  $C_T$ s of SARS-CoV-2 RNA of 177 NPS and 202 SPT (overall dataset)  
441 and **D.** 112 NPS and 91 SPT positive samples. Each data point represents the mean and error of

442 the  $C_T$ s obtained daily in a period of 35 days. NPS and SPT linear regression curve are shown in  
443 blue and grey respectively, and the 95% CI for each slope is shown in light blue (NPS) and light  
444 grey (SPT). The slopes and Y intercept were compared using  $p$  value using a two-tailed test.



445

446 **Figure 2. SPT has a higher correlation with NPS during the first 10 days of symptoms. A.**

447 Overall paired NPS vs SPT samples acquired during 36 days of follow-up ( $n = 167$ ) were

448 obtained from 30 mild and 41 hospitalized patients were plotted against each other. **B.** Paired

449 NPS vs SPT paired samples ( $n = 47$ ) obtained from 25 outpatients and 14 hospitalized patients

450 during first ten days follow up after the symptom's onset. **C.** Paired samples ( $n = 120$ ) obtained

451 from 25 outpatients and 37 hospitalized patients after ten days of the symptoms onset and up to

452 30 days of follow-up. Spearman's correlation analyses results are shown on each graph. LOD =


453 Limit of detection ( $CT < 39.02$  equivalent to  $3.5$  copies/ $\mu$ L). For graphical representation a  $C_T$  of

454 50 was assigned to negative samples. **D.** Overall matched pairs comparison of samples collected

455 during the first ten days (**E**) and from days 11 to 36 (**F**) since onset of symptoms. Wilcoxon

456 matched-pairs signed ranks test was used to compare the  $C_T$ s obtained from NPS (orange dots)

457 and SPT (blue dots) for the indicated time period.



458

459 **Figure 3. Comparison of costs of using SPT under clinical settings for diagnostics of SARS-**  
460 **CoV-2. A.** Analysis of actual cost of obtaining SPT versus NPS samples through two different  
461 health network providers. **B.** Calculated cost reduction of collecting SPT versus NP specimens  
462 through a health network versus a private provider. Analyses performed considering 1,000  
463 samples under different health services.